Study links normal stem cells to aggressive prostate cancer
A study that revealed new findings about prostate cells may point to future strategies for treating aggressive and therapy-resistant forms of prostate cancer.
The study proved that the prostate basal cell layer contains adult stem cells which possess a unique gene expression profile resembling the deadliest form of prostate cancer. The research was led by The University of Texas MD Anderson Cancer Center with findings published...
Cancer specialists honored for excellence in patient care and research
Nearly 50 faculty members at The University of Texas MD Anderson Cancer Center were honored for their exceptional efforts in the fight against...
Making Cancer History® in Sarasota
The University of Texas MD Anderson Cancer Center returns to Sarasota, Fla. March 5 for its signature Making Cancer History® Seminar. Renowned...
MD Anderson receives $14 million in CPRIT research funding to recruit top talent
The University of Texas MD Anderson Cancer Center was awarded $14 million this week from the Cancer Prevention and Research Institute of Texas (CPRIT) for the recruitment of three cancer scientists. The awards include $12 million for recruitment of two senior researchers and $2 million for a first-time, tenure-track faculty member
The awards accounted for 54 percent of the $26 million CPRIT awarded this week for recruitment of...
MD Anderson researchers propose new staging for HPV-related oropharyngeal cancer
Human papillomavirus (HPV) status is a strong predictor of prognosis for patients with oropharyngeal carcinoma (OPC), but the current staging...
First-in-class drug ONC201shows potential for some blood cancers
ONC201, an anti-cancer drug that triggers cell death in various tumor types, may have clinical potential for some blood cancers...
MD Anderson’s Making Cancer History® Seminar returns to Palm Beach
The University of Texas MD Anderson Cancer Center will share novel research findings, cancer prevention tips and advances driven by the institution...
MD Anderson shares in $13.4 million award to study treatment for low-grade DCIS
Prospective, randomized trial will compare surgery, active surveillance; evaluate quality of life
____________________________________...